What is CytomX Therapeutics's PP&E (net)?

CytomX Therapeutics (CTMX) reported PP&E (net) of $1.09M in Q1 2026.

How has CytomX Therapeutics's PP&E (net) changed year-over-year?

CytomX Therapeutics's PP&E (net) decreased by 51.1% year-over-year, from $2.23M to $1.09M.

What is the long-term trend for CytomX Therapeutics's PP&E (net)?

Over 5 years (2020 to 2025), CytomX Therapeutics's PP&E (net) has grown at a -28.4% compound annual growth rate (CAGR), from $6.95M to $1.3M.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

CytomX Therapeutics CTMX PP&E (Net)

PP&E (Net) at other companies

PfizerPFE

$19.4B+5.8%

AmgenAMGN

$8.22B+23.0%

Janux TherapeuticsJANX

$3.55M-28.3%

Allogene TherapeuticsALLO

$70.02M-15.6%

Vor BiopharmaVOR

$565K-90.6%

Design Therapeutics, Inc.DSGN

$824K-40.2%

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's PP&E (net)?: CytomX Therapeutics (CTMX) reported PP&E (net) of $1.09M in Q1 2026.
How has CytomX Therapeutics's PP&E (net) changed year-over-year?: CytomX Therapeutics's PP&E (net) decreased by 51.1% year-over-year, from $2.23M to $1.09M.
What is the long-term trend for CytomX Therapeutics's PP&E (net)?: Over 5 years (2020 to 2025), CytomX Therapeutics's PP&E (net) has grown at a -28.4% compound annual growth rate (CAGR), from $6.95M to $1.3M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.